Angeles has built her career at the crossroads of science and regulation. From academic research at CNB and CNIC to leadership roles in biotech and global consulting firms like Asphalion, Parexel, Pharmalex, Scendea, and ProRetina, she’s developed a reputation for translating complexity into action — guiding companies through challenging regulatory landscapes while keeping innovation moving.
She has a strong track record of building and scaling teams, launching new service offerings, and leading cross-functional projects across scientific, regulatory, and commercial domains.
A global perspective on the future of regulation
Having worked closely with health authorities in the US, UK, and EU, Angeles brings valuable international perspective to her role at QbD Group. She’s especially interested in the intersection of data, AI, and regulation — and how these evolving areas can unlock faster, more accessible healthcare innovation for patients worldwide.
As Division Head, she’ll play a key role in shaping the future of our Regulatory Affairs services and supporting clients across all corners of the life sciences industry — from biotech startups to established global players.
Angeles’s mix of experience, strategic thinking, and purpose-driven leadership is a perfect match for QbD Group. We’re thrilled to have her on board as we continue to expand and evolve our regulatory services.
- Bart Van Acker, founder and CEO of QbD Group
QbD Group
Need expert guidance?
Our experts are ready to help you with your life sciences project.
